ANIP
ANI Pharmaceuticals, Inc.
Set alert
72.00 USD -1.16 -1.59%
71.90 Day range 73.54
70.16 52-week range 94.48
- YTD
- -8.79%
- 1 year
- -21.68%
- Open
- 73.27
- Prev close
- 73.16
- Mkt cap
- 1.65B
- Vol
- 286.90K
- Avg vol
- 386.56K
- EPS
- 4.62
- P/E
- 15.58
- Div yield
- 0.00%
More statistics
- Low
- 71.90
- High
- 73.54
- Forward P/E
- 7.14
- Beta
- 0.49
- Short ratio
- 8.21
- Inst. own
- 107.18%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 73.06
- 200-d avg
- 77.72
- 1y target
- 105.78
Key statistics
- Market cap
- 1.66B
- Enterprise value
- 1.82B
- Trailing P/E
- 15.65
- Forward P/E
- 7.14
- PEG ratio
- 1.81
- Price / sales
- 1.70
- Price / book
- 2.59
- EPS (TTM)
- 4.62
- Beta
- 0.49
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 11.07%
- Revenue (TTM)
- 978.38M
- Revenue growth
- 25.90%
- Free cash flow
- 132.21M
- Total cash
- 376.96M
- Total debt
- 626.03M
- Return on equity
- 20.46%
- Shares outstanding
- 22.96M
- Short % of float
- 18.41%
- 50-day average
- 73.06
- 200-day average
- 77.72
Analyst view
Consensus: buy
Buy
Price target (mean) 105.78 +46.9% upside
Now 72.00
- Target (low)
- 85.00
- Target (mean)
- 105.78
- Target (high)
- 121.00
Ratings (0m) 9 7 buy · 2 hold · 0 sell
- Strong buy3
- Buy4
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 2.18.
Financials — quick view
ANIP Revenue — quarterly 266.04M
ANIP Net income — quarterly 24.71M
ANIP EPS — quarterly 1.09
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 2.18 | — | — | — |
| Aug 7, 2026 | Jun 30, 2026 | 2.04 | 2.21 | +0.17 | +8.33% |
| May 8, 2026 | Mar 31, 2026 | 1.28 | 2.05 | +0.77 | +60.16% |
| Feb 27, 2026 | Dec 31, 2025 | 1.99 | 2.33 | +0.34 | +17.09% |
| Nov 7, 2025 | Sep 30, 2025 | 1.74 | 2.04 | +0.30 | +17.24% |
| Aug 8, 2025 | Jun 30, 2025 | 1.38 | 1.80 | +0.42 | +30.43% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | init | — | Perform |
| Aug 10, 2026 | Guggenheim | main | Buy | Buy |
| Aug 10, 2026 | Canaccord Genuity | main | Hold | Hold |
| Jul 17, 2026 | Canaccord Genuity | init | — | Hold |
| Jul 10, 2026 | Guggenheim | reit | Buy | Buy |
| Jan 16, 2026 | Guggenheim | main | Buy | Buy |
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- anipharmaceuticals.com
News
- ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET
- ANI Pharmaceuticals Launches Duloxetine Delayed-Release Capsules 20, 30 And 60 Mg, Generic Version Of Reference Listed Drug Cymbalta
- ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules
- ANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells $388,206.00 in Stock
- Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
- These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
- Head to Head Comparison: ANI Pharmaceuticals (NASDAQ:ANIP) and Talphera (NASDAQ:TLPH)
- ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting
- Implied Volatility Surging for ANI Pharmaceuticals Stock Options
- ANI Pharmaceuticals: Cortrophin's Q4 Test, With Generics Funding The Build
Your note
Sign in to keep a note on ANIP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CAREY STEPHEN P. | Chief Financial Officer | Sale | Sep 28, 2026 | 168,993 |
| COOK MEREDITH | General Counsel | Sale | Oct 12, 2026 | 73,424 |
| DAVIS KRISTA | Officer | Sale | Mar 8, 2026 | 51,946 |
| GASSERT CHAD | Officer | Stock Award(Grant) | Feb 25, 2026 | 233,406 |
| GUTWERG ORI | Officer | Sale | Aug 9, 2026 | 75,534 |
| HAUGHEY THOMAS J | Director | Sale | Jun 7, 2026 | 38,878 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 12.89% | 2,958,646 | 213.92M | Jun 29, 2026 |
| Soleus Capital Management, L.P. | 3.78% | 867,760 | 62.74M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.65% | 838,224 | 60.61M | Jun 29, 2026 |
| State Street Corporation | 3.62% | 831,647 | 60.13M | Jun 29, 2026 |
| Tang Capital Management, LLC | 3.08% | 707,500 | 51.16M | Jun 29, 2026 |
| Dimensional Fund Advisors LP | 2.72% | 623,463 | 45.08M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.22% | 1,198,642 | 86.67M | Sep 29, 2026 |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 3.25% | 745,302 | 53.89M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.65% | 609,433 | 44.07M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.31% | 529,877 | 38.31M | Sep 29, 2026 |
| OBERWEIS FUNDS-Oberweis Micro-Cap Fund | 1.12% | 256,300 | 18.53M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.98% | 224,189 | 16.21M | Jul 30, 2026 |